logo-loader
Close Brothers Group

Close Brothers reports solid performance as financial year draws to close

The FTSE 250 merchant bank said it had performed well across all divisions, with the banking division increasing its loan book 6.6% over the 11 months to £7.3bn

Piggy bank
The group’s asset management division saw managed assets rise by 14% to £10.2bn

Close Brothers Group PLC (LON:CBG) expects a good result for its current financial year following a strong performance over the last 11 months.

In a trading update, the FTSE 250 merchant bank said it had performed well across all of its divisions, with the banking division increasing its loan book 6.6% over the 11 months to £7.3bn.

READ: Berenberg blights Close Brothers, downgrading rating to ‘hold’ from ‘buy’ post-results

Within the division, commercial and property lending saw good growth, while retail business was broadly flat. Elsewhere, the group’s Winterflood Securities business delivered a good performance with high volumes.

The firm also said that its bad debt ratio had remained low across its businesses while its net interest margin had remained in line with the previous year at 8%.

Meanwhile, the group’s asset management division saw managed assets rise by 14% to £10.2bn over the year to date, while total client assets grew 8% to £12bn.

Looking ahead

Looking ahead, Close Brothers said it expected a good result for the full-year, in line with market expectations.

In a note to clients, City broker Numis upgraded the bank to ‘Add’ from ‘Hold’, saying that “economic profit is consistently and sustainably high” due to the group’s focus on new high risk-adjusted margin and specialist lending market segments.

Analysts at the broker also highlighted that Close Brothers had seen a 31-year earnings per share (EPS) compound annual growth rate (CAGR) of 11%, while never cutting its dividend or engaging in a rescue rights issue.

In late-morning trading Wednesday, Close Brothers shares were up 0.9% at 1,537p.

Quick facts: Close Brothers Group

Price: £12.68

Market: LSE
Market Cap: £1.92 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

7 hours, 42 minutes ago

2 min read